Deamidation and Isomerization in Peptides
Deamidation converts certain amide-containing side chains into acidic products. In peptides, asparagine is often more susceptible than glutamine, especially in flexible sequence contexts.
Asparagine pathway
Asparagine may form a cyclic succinimide intermediate. Hydrolysis can then produce aspartate or isoaspartate. The isoaspartate product inserts an extra methylene group into the backbone path, altering local structure without changing elemental composition relative to aspartate.
Influencing factors
- neighboring residues
- pH
- temperature
- water activity
- conformation
- ionic strength
- buffer species
- solid versus solution state
Analytical consequences
Deamidation produces a mass increase and often changes charge and retention. Isoaspartate may be difficult to distinguish from aspartate by intact mass because both have the same mass.
Potential methods include:
- ion-exchange chromatography
- reversed-phase chromatography
- LC-MS peptide mapping
- isoaspartate-specific enzymatic methods
- capillary electrophoresis
Glutamine deamidation
Glutamine can also deamidate, often more slowly and through different structural constraints. N-terminal glutamine may cyclize to pyroglutamate, which is a related but distinct modification.
Frequently asked questions
Does a mass increase prove where deamidation occurred?
No. Localization generally requires fragment-level analysis.
Can deamidation happen in dry material?
Yes, though the rate and mechanism depend on residual moisture and matrix mobility.
Is isoaspartate the same as aspartate?
They have the same mass but different backbone connectivity.
Can pH optimization prevent all deamidation?
No. It can reduce risk but sequence and formulation remain important.
Key takeaways
Deamidation is a chemically and structurally complex pathway. Intact mass can reveal change, but localization and isoaspartate assessment often require orthogonal methods.
References
- ICH Q1A(R2). Stability Testing of New Drug Substances and Products.
- Manning MC, et al. Stability of protein pharmaceuticals. Pharm Res. 1989.
- Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci. 1999.
- FDA. Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry.
- ICH Q2(R2). Validation of Analytical Procedures.
- ICH Q14. Analytical Procedure Development.
TSMS Labs educational disclaimer: For laboratory research and educational purposes only. Not for human consumption. This content is not medical, clinical, or regulatory advice.